****Die Chance heute doch noch Kohle zu machen**** - 500 Beiträge pro Seite

[Zepping]

Laut Reuters: Dramatischer Fortschritt in der Aidsforschung, a. Biotechunternehmen entwickelt neues Medikament
Habe auch gerade die WKN ausfindig: 885823
Science Headlines
Sources: Reuters
Sunday April 16 9:24 PM ET
Gilead Says Tenofovir Pill Effective in AIDS Patients
By Deena Beasley
LOS ANGELES (Reuters) - Gilead Sciences Inc. (NasdaqNM:GILD - news) said on Sunday that early results from a mid-stage trial of its experimental AIDS pill, tenofovir, show it reduced the viral load of patients.
A decrease in viral load is considered meaningful, according to the company, which unveiled the data at the International Conference for Antiviral Research in Baltimore.
Tenofovir belongs to a new class of drugs called nucleotide analogs, which work by blocking reverse transcriptase, an enzyme crucial to HIV replication.
``It is well established that any meaningful reduction in viral load translates into clinical benefits for patients. A 7-fold decrease with only one agent is almost unheard of,`` Dr. Norbert 0Bischofberger, senior vice president of research and development at Gilead, said in an interview.
Gilead, based in Foster City, Calif., said the data is particularly significant since it shows that tenofovir is effective in otherwise resistant patients out to at least 48 weeks.
``There is not that much left that can work for them. This study shows long-term tolerability and safety`` Bischofberger said.
The 48-week Phase II trial enrolled 189 patients who had received antiretroviral therapy for several years and had been on a stable antiretroviral regimen for at least 8 weeks prior to entering the study.
The 41 patients receiving the highest dose, 300 mg, of the once-daily tenofovir pill saw an average 7-fold decrease in viral load, while patients on lower doses experienced less dramatic, but still meaningful, decreases, Gilead said.
``The regimen is simple, and the safety profile to date is very encouraging, suggesting that tenofovir may become an important new option for patients whose alternatives are limited by viral resistance,`` Dr. Melanie Thompson, director of the AIDS Research Consortium of Atlanta and a clinical investigator, said in a statement.
Late last year, Gilead abandoned the study of adefovir, a drug chemically related to tenofovir, as a treatment for AIDS, after a U.S. Food and Drug Administration (FDA) advisory panel said it needed to see further clinical studies.
Having classified HIV and AIDS as chronic diseases, the FDA requires that drug candidates be effective for at least a year.
Gilead began enrollment last November of a Phase III trial of tenofovir for patients resistant to other treatments and plans to launch another pivotal trial in ``treatment-naive`` AIDS patients next month, Bischofberger said.
He noted that tenofovir has not caused the type of kidney function problems associated with higher doses of adefovir. ``We have studied renal function in some patients up to 76 weeks and we have not seen anything,`` he said.

[FJB]

http://www.gilead.com/webpage_templates/frame_home.php3

dort gibts ne Menge Infos zu GILEAD
und die beiden neuen News (englisch aber sehr informativ)

arbeiten erfolgreich an verschiedenen Medikamenten

schöne Ostern wünscht
FJB